|
EP2505646A1
(en)
|
2006-05-05 |
2012-10-03 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating expression of CRP
|
|
EP2410053B2
(en)
*
|
2006-10-18 |
2020-07-15 |
Ionis Pharmaceuticals, Inc. |
Antisense compounds
|
|
US8580756B2
(en)
*
|
2007-03-22 |
2013-11-12 |
Santaris Pharma A/S |
Short oligomer antagonist compounds for the modulation of target mRNA
|
|
US8318496B2
(en)
*
|
2007-10-04 |
2012-11-27 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for improving cellular uptake of oligomeric compounds
|
|
US8846639B2
(en)
|
2008-04-04 |
2014-09-30 |
Isis Pharmaceutical, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
|
|
CA2740785C
(en)
|
2008-10-15 |
2017-06-20 |
Isis Pharmaceuticals, Inc. |
Modulation of factor 11 expression
|
|
BRPI0923225A2
(pt)
|
2008-12-02 |
2016-10-04 |
Chiralgen Ltd |
metodo para sintese de acidos nucleicos modificados no atomo de fosforo
|
|
EP2451461A4
(en)
|
2009-07-06 |
2013-05-29 |
Ontorii Inc |
NOVEL NUCLEIC ACID PRODRUGS AND METHOD OF USE THEREOF
|
|
JP6018506B2
(ja)
|
2010-02-08 |
2016-11-02 |
アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． |
対立遺伝子多様体の選択的低減
|
|
ES2733708T3
(es)
|
2010-02-08 |
2019-12-02 |
Ionis Pharmaceuticals Inc |
Reducción selectiva de variantes alélicas
|
|
ES2756326T3
(es)
|
2010-07-19 |
2020-04-27 |
Ionis Pharmaceuticals Inc |
Modulación de la expresión de distrofia miotónica-proteína quinasa (DMPK)
|
|
US8648053B2
(en)
|
2010-10-20 |
2014-02-11 |
Rosalind Franklin University Of Medicine And Science |
Antisense oligonucleotides that target a cryptic splice site in Ush1c as a therapeutic for Usher syndrome
|
|
US9920317B2
(en)
|
2010-11-12 |
2018-03-20 |
The General Hospital Corporation |
Polycomb-associated non-coding RNAs
|
|
EP3702460A1
(en)
|
2010-11-12 |
2020-09-02 |
The General Hospital Corporation |
Polycomb-associated non-coding rnas
|
|
EP3521451A1
(en)
|
2010-11-17 |
2019-08-07 |
Ionis Pharmaceuticals, Inc. |
Modulation of alpha synuclein expression
|
|
US10017764B2
(en)
|
2011-02-08 |
2018-07-10 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
|
WO2012161806A1
(en)
*
|
2011-02-25 |
2012-11-29 |
Isis Pharmaceuticals, Inc. |
Modulation of stat3 expression
|
|
SI3505528T1
(sl)
*
|
2011-04-21 |
2021-04-30 |
Glaxo Group Limited |
Modulacija izražanja virusa hepatitisa B (HBV)
|
|
WO2012151324A1
(en)
|
2011-05-02 |
2012-11-08 |
Isis Pharmaceuticals, Inc. |
Antisense compounds targeting genes associated with usher syndrome
|
|
CN107365339A
(zh)
|
2011-07-19 |
2017-11-21 |
波涛生命科学有限公司 |
合成官能化核酸的方法
|
|
US20140303235A1
(en)
|
2011-08-11 |
2014-10-09 |
Isis Pharmaceuticals, Inc. |
Linkage modified gapped oligomeric compounds and uses thereof
|
|
HK1200484A1
(zh)
|
2011-09-14 |
2015-08-07 |
Translate Bio Ma, Inc. |
多聚寡核苷酸化合物
|
|
US9243291B1
(en)
*
|
2011-12-01 |
2016-01-26 |
Isis Pharmaceuticals, Inc. |
Methods of predicting toxicity
|
|
CN104254610A
(zh)
*
|
2012-03-12 |
2014-12-31 |
桑塔里斯制药公司 |
调节atxn3表达的组合物和方法
|
|
EP3336189A1
(en)
|
2012-04-20 |
2018-06-20 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
|
EA201492120A1
(ru)
|
2012-05-16 |
2015-10-30 |
Рана Терапьютикс, Инк. |
Композиции и способы для модулирования экспрессии atp2a2
|
|
EA201492118A1
(ru)
*
|
2012-05-16 |
2015-04-30 |
Рана Терапьютикс, Инк. |
Композиции и способы для модулирования экспрессии pten
|
|
CN104540946A
(zh)
|
2012-05-16 |
2015-04-22 |
Rana医疗有限公司 |
用于调节utrn表达的组合物和方法
|
|
US10837014B2
(en)
|
2012-05-16 |
2020-11-17 |
Translate Bio Ma, Inc. |
Compositions and methods for modulating SMN gene family expression
|
|
CN104583402A
(zh)
|
2012-05-16 |
2015-04-29 |
Rana医疗有限公司 |
用于调节mecp2表达的组合物和方法
|
|
JP2015523854A
(ja)
|
2012-05-16 |
2015-08-20 |
ラナ セラピューティクス インコーポレイテッド |
Ｓｍｎ遺伝子ファミリー発現を調節するための組成物及び方法
|
|
US10174315B2
(en)
|
2012-05-16 |
2019-01-08 |
The General Hospital Corporation |
Compositions and methods for modulating hemoglobin gene family expression
|
|
US9574193B2
(en)
|
2012-05-17 |
2017-02-21 |
Ionis Pharmaceuticals, Inc. |
Methods and compositions for modulating apolipoprotein (a) expression
|
|
US20160002624A1
(en)
|
2012-05-17 |
2016-01-07 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide compositions
|
|
RU2624028C2
(ru)
|
2012-05-24 |
2017-06-30 |
Ионис Фармасьютикалз, Инк. |
Способы и композиции для модулирования экспрессии аполипопротеина (а)
|
|
US9828602B2
(en)
|
2012-06-01 |
2017-11-28 |
Ionis Pharmaceuticals, Inc. |
Antisense compounds targeting genes associated with fibronectin
|
|
WO2013181666A2
(en)
|
2012-06-01 |
2013-12-05 |
Isis Pharmaceuticals, Inc. |
Antisense compounds targeting genes associated with fibronectin
|
|
SG11201500243WA
(en)
|
2012-07-13 |
2015-04-29 |
Shin Nippon Biomedical Lab Ltd |
Chiral nucleic acid adjuvant
|
|
DK2872147T3
(da)
|
2012-07-13 |
2023-02-20 |
Wave Life Sciences Ltd |
Fremgangsmåde til fremstilling af kirale oligonukleotider
|
|
WO2014010250A1
(en)
|
2012-07-13 |
2014-01-16 |
Chiralgen, Ltd. |
Asymmetric auxiliary group
|
|
US20150247141A1
(en)
|
2012-09-14 |
2015-09-03 |
Rana Therapeutics, Inc. |
Multimeric oligonucleotide compounds
|
|
US9695418B2
(en)
|
2012-10-11 |
2017-07-04 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and uses thereof
|
|
EP2906255B1
(en)
*
|
2012-10-12 |
2023-02-22 |
Ionis Pharmaceuticals, Inc. |
Antisense compounds and uses thereof
|
|
BR112015013105B1
(pt)
*
|
2012-12-05 |
2022-02-08 |
Alnylam Pharmaceuticals, Inc |
Agente de rnai de fita dupla capaz de inibir a expressão de pcsk9, seus usos, composição farmacêutica e método de inibição da expressão de pcsk9 em uma célula in vitro
|
|
WO2014132671A1
(en)
|
2013-03-01 |
2014-09-04 |
National University Corporation Tokyo Medical And Dental University |
Chimeric single-stranded antisense polynucleotides and double-stranded antisense agent
|
|
PT2970974T
(pt)
*
|
2013-03-14 |
2017-11-29 |
Alnylam Pharmaceuticals Inc |
Composições de irna de componente do complemento c5 e métodos para a sua utilização
|
|
PL2992098T3
(pl)
|
2013-05-01 |
2019-09-30 |
Ionis Pharmaceuticals, Inc. |
Kompozycje i sposoby modulowania ekspresji hbv i ttr
|
|
TW201536329A
(zh)
|
2013-08-09 |
2015-10-01 |
Isis Pharmaceuticals Inc |
用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
|
|
US11162096B2
(en)
|
2013-10-14 |
2021-11-02 |
Ionis Pharmaceuticals, Inc |
Methods for modulating expression of C9ORF72 antisense transcript
|
|
DK3077510T3
(da)
|
2013-12-02 |
2020-06-08 |
Ionis Pharmaceuticals Inc |
Antisense-forbindelser og anvendelser deraf
|
|
EP3095461A4
(en)
|
2014-01-15 |
2017-08-23 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
|
|
WO2015108046A1
(ja)
|
2014-01-15 |
2015-07-23 |
株式会社新日本科学 |
抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
|
|
EP3095459A4
(en)
|
2014-01-15 |
2017-08-23 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
|
|
EP3094728B1
(en)
|
2014-01-16 |
2022-03-09 |
Wave Life Sciences Ltd. |
Chiral design
|
|
WO2015143245A1
(en)
|
2014-03-19 |
2015-09-24 |
Isis Pharmaceuticals, Inc. |
Methods for modulating ataxin 2 expression
|
|
SI3119888T1
(sl)
|
2014-03-19 |
2021-11-30 |
Ionis Pharmaceuticals, Inc. |
Sestavki za moduliranje izražanja ataksina 2
|
|
HUE050704T2
(hu)
|
2014-04-01 |
2020-12-28 |
Biogen Ma Inc |
Összetételek a SOD-1 expressziójának modulálására
|
|
CR20160554A
(es)
|
2014-05-01 |
2017-03-07 |
Ionis Pharmaceuticals Inc |
Composiciones y métodos para modular la expresión del factor b del complemento
|
|
WO2015187989A1
(en)
|
2014-06-04 |
2015-12-10 |
Isis Pharmaceuticals, Inc. |
Antisense compounds targeting apolipoprotein e receptor 2
|
|
GB201410693D0
(en)
|
2014-06-16 |
2014-07-30 |
Univ Southampton |
Splicing modulation
|
|
EP3161159B1
(en)
|
2014-06-25 |
2020-08-05 |
The General Hospital Corporation |
Targeting human satellite ii (hsatii)
|
|
WO2016040748A1
(en)
|
2014-09-12 |
2016-03-17 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for detection of smn protein in a subject and treatment of a subject
|
|
US10533172B2
(en)
|
2014-09-18 |
2020-01-14 |
The University Of British Columbia |
Allele-specific therapy for huntington disease haplotypes
|
|
CN107109411B
(zh)
|
2014-10-03 |
2022-07-01 |
冷泉港实验室 |
核基因输出的定向增加
|
|
WO2016070060A1
(en)
|
2014-10-30 |
2016-05-06 |
The General Hospital Corporation |
Methods for modulating atrx-dependent gene repression
|
|
EP3221329A1
(en)
*
|
2014-11-19 |
2017-09-27 |
Roche Innovation Center Copenhagen A/S |
Lna gapmer oligonucleotides comprising chiral phosphorothioate linkages
|
|
DK3234131T3
(da)
*
|
2014-12-16 |
2020-06-29 |
Roche Innovation Ct Copenhagen As |
Fremgangsmåde til screening af kiral toksicitet
|
|
US10793855B2
(en)
|
2015-01-06 |
2020-10-06 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of C9ORF72 antisense transcript
|
|
US10538763B2
(en)
|
2015-01-16 |
2020-01-21 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulation of DUX4
|
|
ES2893114T3
(es)
|
2015-02-04 |
2022-02-08 |
Bristol Myers Squibb Co |
Métodos para seleccionar moléculas terapéuticas
|
|
CA2975525A1
(en)
|
2015-02-04 |
2016-08-11 |
F. Hoffmann-La Roche Ag |
Tau antisense oligomers and uses thereof
|
|
WO2016130963A1
(en)
*
|
2015-02-13 |
2016-08-18 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating rna
|
|
WO2016130943A1
(en)
|
2015-02-13 |
2016-08-18 |
Rana Therapeutics, Inc. |
Hybrid oligonucleotides and uses thereof
|
|
US11129844B2
(en)
|
2015-03-03 |
2021-09-28 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating MECP2 expression
|
|
US10900036B2
(en)
|
2015-03-17 |
2021-01-26 |
The General Hospital Corporation |
RNA interactome of polycomb repressive complex 1 (PRC1)
|
|
WO2016167780A1
(en)
|
2015-04-16 |
2016-10-20 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
|
CN117965536A
(zh)
|
2015-07-22 |
2024-05-03 |
波涛生命科学有限公司 |
寡核苷酸组合物及其方法
|
|
WO2017053781A1
(en)
|
2015-09-25 |
2017-03-30 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating ataxin 3 expression
|
|
CN108603230A
(zh)
|
2015-10-09 |
2018-09-28 |
南安普敦大学 |
基因表达的调节与蛋白质表达失调的筛选
|
|
EP3389670A4
(en)
|
2015-12-04 |
2020-01-08 |
Ionis Pharmaceuticals, Inc. |
METHODS OF TREATING BREAST CANCER
|
|
CN116059236A
(zh)
|
2015-12-14 |
2023-05-05 |
冷泉港实验室 |
用于治疗常染色体显性精神发育迟滞5型和Dravet综合征的反义寡聚体
|
|
US11096956B2
(en)
|
2015-12-14 |
2021-08-24 |
Stoke Therapeutics, Inc. |
Antisense oligomers and uses thereof
|
|
WO2017117496A1
(en)
|
2015-12-31 |
2017-07-06 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing ataxin-2 expression
|
|
EP3400300A4
(en)
|
2016-01-05 |
2019-08-07 |
Ionis Pharmaceuticals, Inc. |
PROCESS FOR REDUCING LRRK2 EXPRESSION
|
|
US11384112B2
(en)
|
2016-02-17 |
2022-07-12 |
Tokyo Institute Of Technology |
Artificial nucleoside and artificial nucleotide, and artificial oligonucleotide
|
|
WO2017161168A1
(en)
|
2016-03-16 |
2017-09-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of dyrk1b expression
|
|
CA3013799A1
(en)
|
2016-03-16 |
2017-09-21 |
Ionis Pharmaceuticals, Inc. |
Methods of modulating keap1
|
|
EP3452596A4
(en)
|
2016-05-04 |
2020-03-18 |
Wave Life Sciences Ltd. |
OLIGONUCLEOTIDE COMPOSITIONS AND RELATED METHODS
|
|
AU2017286811A1
(en)
|
2016-06-17 |
2018-11-22 |
Ionis Pharmaceuticals, Inc. |
Modulation of gys1 expression
|
|
AU2017285350A1
(en)
|
2016-06-17 |
2018-12-20 |
F. Hoffmann-La Roche Ag |
Nucleic acid molecules for reduction of PAPD5 or PAPD7 mRNA for treating hepatitis B infection
|
|
AU2017291960B2
(en)
|
2016-07-05 |
2024-03-14 |
Biomarin Technologies B.V. |
Pre-mRNA splice switching or modulating oligonucleotides comprising bicyclic scaffold moieties, with improved characteristics for the treatment of genetic disorders
|
|
EP3516061A1
(en)
|
2016-09-23 |
2019-07-31 |
Synthena AG |
Mixed tricyclo-dna, 2'-modified rna oligonucleotide compositions and uses thereof
|
|
US11433089B2
(en)
|
2016-09-23 |
2022-09-06 |
National University Corporation Tokyo Medical And Dental University |
Blood-brain barrier permeable heteroduplex nucleic acid
|
|
WO2018055577A1
(en)
*
|
2016-09-23 |
2018-03-29 |
Synthena Ag |
Mixed tricyclo-dna, 2'-modified rna oligonucleotide compositions and uses thereof
|
|
US11260134B2
(en)
|
2016-09-29 |
2022-03-01 |
National University Corporation Tokyo Medical And Dental University |
Double-stranded nucleic acid complex having overhang
|
|
WO2018067900A1
(en)
|
2016-10-06 |
2018-04-12 |
Ionis Pharmaceuticals, Inc. |
Method of conjugating oligomeric compounds
|
|
JOP20190104A1
(ar)
|
2016-11-10 |
2019-05-07 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن atxn3
|
|
US20180193270A1
(en)
|
2016-11-29 |
2018-07-12 |
PureTech Health LLC |
Exosomes for delivery of therapeutic agents
|
|
US11033570B2
(en)
|
2016-12-02 |
2021-06-15 |
Cold Spring Harbor Laboratory |
Modulation of Lnc05 expression
|
|
JP7188087B2
(ja)
|
2017-02-06 |
2022-12-13 |
日産化学株式会社 |
一本鎖オリゴヌクレオチド
|
|
US11261440B2
(en)
|
2017-02-21 |
2022-03-01 |
Osaka University |
Antisense oligonucleic acid
|
|
JOP20190215A1
(ar)
|
2017-03-24 |
2019-09-19 |
Ionis Pharmaceuticals Inc |
مُعدّلات التعبير الوراثي عن pcsk9
|
|
JP6974872B2
(ja)
|
2017-06-30 |
2021-12-01 |
国立大学法人 東京医科歯科大学 |
ヘテロ二本鎖型ａｎｔｉｍｉＲ
|
|
AU2018316159A1
(en)
|
2017-08-08 |
2020-02-06 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods thereof
|
|
CA3071033A1
(en)
|
2017-08-18 |
2019-02-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of the notch signaling pathway for treatment of respiratory disorders
|
|
KR20260009385A
(ko)
|
2017-08-25 |
2026-01-19 |
스톡 테라퓨틱스, 인크. |
병태 및 질환 치료용 안티센스 올리고머
|
|
US10517889B2
(en)
|
2017-09-08 |
2019-12-31 |
Ionis Pharmaceuticals, Inc. |
Modulators of SMAD7 expression
|
|
CN111226114A
(zh)
|
2017-10-13 |
2020-06-02 |
罗氏创新中心哥本哈根有限公司 |
用部分立体限定的寡核苷酸子文库鉴定反义寡核苷酸改进的立体限定硫代磷酸酯寡核苷酸变体的方法
|
|
KR20200030594A
(ko)
|
2017-10-16 |
2020-03-20 |
에프. 호프만-라 로슈 아게 |
B형 간염 감염을 치료하기 위한 PAPD5 및 PAPD7 mRNA의 감소용 핵산 분자
|
|
TWI809004B
(zh)
|
2017-11-09 |
2023-07-21 |
美商Ionis製藥公司 |
用於降低snca表現之化合物及方法
|
|
WO2019115416A2
(en)
|
2017-12-11 |
2019-06-20 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating fndc3b expression
|
|
WO2019115417A2
(en)
|
2017-12-12 |
2019-06-20 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating rb1 expression
|
|
CA3085211A1
(en)
|
2017-12-21 |
2019-06-27 |
F. Hoffmann-La Roche Ag |
Companion diagnostic for htra1 rna antagonists
|
|
WO2019126641A2
(en)
|
2017-12-21 |
2019-06-27 |
Ionis Pharmaceuticals, Inc. |
Modulation of frataxin expression
|
|
US20200339982A1
(en)
|
2017-12-22 |
2020-10-29 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides comprising a phosphorodithioate internucleoside linkage
|
|
CN111448317B
(zh)
|
2017-12-22 |
2025-07-04 |
罗氏创新中心哥本哈根有限公司 |
包含二硫代磷酸酯核苷间键的缺口聚物寡核苷酸
|
|
CN111448316B
(zh)
|
2017-12-22 |
2025-02-14 |
罗氏创新中心哥本哈根有限公司 |
新的硫代亚磷酰胺
|
|
CN111699258A
(zh)
|
2018-01-10 |
2020-09-22 |
哥本哈根罗氏创新中心 |
用于调控pias4表达的寡核苷酸
|
|
US20210095275A1
(en)
|
2018-01-12 |
2021-04-01 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating gsk3b expression
|
|
CA3088522A1
(en)
|
2018-01-15 |
2019-07-18 |
Ionis Pharmaceuticals, Inc. |
Modulators of dnm2 expression
|
|
WO2019141656A1
(en)
|
2018-01-17 |
2019-07-25 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating erc1 expression
|
|
EP3740573A1
(en)
|
2018-01-18 |
2020-11-25 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting srebp1
|
|
WO2019145386A1
(en)
|
2018-01-26 |
2019-08-01 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating csnk1d expression
|
|
BR112020016170A2
(pt)
|
2018-02-09 |
2020-12-15 |
Genentech, Inc. |
Oligonucleotídeos terapêutico e antissenso, conjugado, sal farmaceuticamente aceitável, composição farmacêutica, método in vitro ou in vivo para modular a expressão de tmem106b, método para tratar ou prevenir uma doença, uso do oligonucleotídeo e uso ou método
|
|
AU2019218987B2
(en)
|
2018-02-12 |
2025-04-24 |
Ionis Pharmaceuticals, Inc. |
Modified compounds and uses thereof
|
|
US11674141B2
(en)
|
2018-02-28 |
2023-06-13 |
National University Corporation Tokyo Medical And Dental University |
Ischemic-lesion-site-specific gene therapy
|
|
WO2019169243A1
(en)
|
2018-03-02 |
2019-09-06 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for the modulation of amyloid-beta precursor protein
|
|
TWI840345B
(zh)
|
2018-03-02 |
2024-05-01 |
美商Ionis製藥公司 |
Irf4表現之調節劑
|
|
EP3766972B1
(en)
|
2018-03-14 |
2025-04-23 |
Institute of Science Tokyo |
Nucleic acid complex
|
|
US11851654B2
(en)
|
2018-03-19 |
2023-12-26 |
National University Corporation Tokyo Medical And Dental University |
Nucleic acid with reduced toxicity
|
|
EP3770256A4
(en)
|
2018-03-20 |
2021-12-22 |
Tokyo Institute of Technology |
ANTISENSE OLIGONUCLEOTIDE WITH REDUCED TOXICITY
|
|
WO2019183440A1
(en)
|
2018-03-22 |
2019-09-26 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating fmr1 expression
|
|
JP7262816B2
(ja)
|
2018-03-22 |
2023-04-24 |
国立大学法人 東京医科歯科大学 |
ヘテロ核酸のｂｂｂ通過脂質リガンド
|
|
US20210047646A1
(en)
*
|
2018-04-09 |
2021-02-18 |
The Trustees Of Princeton University |
Compositions Comprising Immune System Activators and Method of Using Same
|
|
WO2019200172A1
(en)
|
2018-04-11 |
2019-10-17 |
Ionis Pharmaceuticals, Inc. |
Modulators of ezh2 expression
|
|
JP2021523227A
(ja)
|
2018-05-04 |
2021-09-02 |
ストーク セラピューティクス，インク． |
コレステリルエステル蓄積症の処置のための方法及び組成物
|
|
US20210371860A1
(en)
|
2018-05-08 |
2021-12-02 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating myh7 expression
|
|
IL277970B2
(en)
|
2018-05-09 |
2025-03-01 |
Ionis Pharmaceuticals Inc |
Oligomeric compounds comprising modified oligonucleotides and conjugated groups for use in the treatment of end-stage renal disease, chronic kidney disease and coronary artery disease
|
|
JP2021522800A
(ja)
|
2018-05-09 |
2021-09-02 |
アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． |
Ａｔｘｎ３発現を低減するための化合物及び方法
|
|
EP3802824A1
(en)
|
2018-06-05 |
2021-04-14 |
F. Hoffmann-La Roche AG |
Oligonucleotides for modulating atxn2 expression
|
|
CA3103429A1
(en)
*
|
2018-06-14 |
2019-12-19 |
Don W. Cleveland |
Compounds and methods for increasing stmn2 expression
|
|
TWI833770B
(zh)
|
2018-06-27 |
2024-03-01 |
美商Ionis製藥公司 |
用於減少 lrrk2 表現之化合物及方法
|
|
WO2020007772A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting gbp-1
|
|
WO2020007700A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting spi1
|
|
WO2020007702A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting bcl2l11
|
|
TWI862501B
(zh)
|
2018-07-03 |
2024-11-21 |
瑞士商赫孚孟拉羅股份公司 |
用於調制 Tau 表現之寡核苷酸
|
|
WO2020007889A1
(en)
|
2018-07-05 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting stat1
|
|
WO2020007826A1
(en)
|
2018-07-05 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting mbtps1
|
|
WO2020011743A1
(en)
|
2018-07-09 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting mafb
|
|
WO2020011653A1
(en)
|
2018-07-09 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting kynu
|
|
WO2020011869A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting tlr2
|
|
WO2020011744A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting cers5
|
|
WO2020011745A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting cers6
|
|
BR112021000538A2
(pt)
|
2018-07-13 |
2021-04-06 |
F. Hoffmann-La Roche Ag |
Oligonucleotídeos para modular a expressão de rtel1
|
|
WO2020018558A1
(en)
|
2018-07-17 |
2020-01-23 |
Aronora, Inc. |
Methods for safely reducing thrombopoietin
|
|
AU2019310097A1
(en)
|
2018-07-25 |
2021-02-04 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing ATXN2 expression
|
|
CN112512584A
(zh)
|
2018-07-27 |
2021-03-16 |
国立大学法人大阪大学 |
用于抑制衰老、预防、改善或治疗衰老相关疾病或症状、或者延长寿命的组合物
|
|
CA3098267A1
(en)
|
2018-07-31 |
2020-02-06 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides comprising a phosphorotrithioate internucleoside linkage
|
|
BR112021001756A2
(pt)
|
2018-07-31 |
2021-05-11 |
Roche Innovation Center Copenhagen A/S |
oligonucleotídeos, oligonucleotídeo gapmer, sal farmaceuticamente aceitável, conjugado, composição farmacêutica, usos de um oligonucleotídeo, método para o tratamento ou profilaxia de uma doença, processo para a fabricação de um oligonucleotídeo e invenção
|
|
EP3830259A4
(en)
|
2018-08-02 |
2022-05-04 |
Dyne Therapeutics, Inc. |
MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
|
|
US11911484B2
(en)
|
2018-08-02 |
2024-02-27 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US12018087B2
(en)
|
2018-08-02 |
2024-06-25 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
|
|
US12097263B2
(en)
|
2018-08-02 |
2024-09-24 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US12370264B1
(en)
|
2018-08-02 |
2025-07-29 |
Dyne Therapeutics, Inc. |
Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
|
|
WO2020038973A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting sptlc1
|
|
WO2020038976A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting usp8
|
|
WO2020038971A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting vcan
|
|
EP3620519A1
(en)
|
2018-09-04 |
2020-03-11 |
F. Hoffmann-La Roche AG |
Use of isolated milk extracellular vesicles for delivering oligonucleotides orally
|
|
JP2022512877A
(ja)
|
2018-11-01 |
2022-02-07 |
エフ．ホフマン－ラ ロシュ アーゲー |
Ｔｉａ１を標的とするアンチセンスオリゴヌクレオチド
|
|
TW202028222A
(zh)
|
2018-11-14 |
2020-08-01 |
美商Ionis製藥公司 |
Foxp3表現之調節劑
|
|
MX2021005758A
(es)
|
2018-11-15 |
2021-09-21 |
Ionis Pharmaceuticals Inc |
Moduladores de la expresión de irf5.
|
|
US12281305B2
(en)
|
2018-11-21 |
2025-04-22 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing prion expression
|
|
EP3894559A4
(en)
*
|
2018-12-03 |
2023-04-05 |
Triplet Therapeutics, Inc. |
METHODS OF TREATMENT OF TRINUCLEOTIDE REPEAT EXPANSION DISORDERS RELATED TO MLH3 ACTIVITY
|
|
JP2022514648A
(ja)
|
2018-12-21 |
2022-02-14 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｃａｒｄ９を標的とするアンチセンスオリゴヌクレオチド
|
|
CN113365607A
(zh)
|
2019-01-25 |
2021-09-07 |
豪夫迈·罗氏有限公司 |
用于口服药物递送的脂质囊泡
|
|
TW202214854A
(zh)
|
2019-01-31 |
2022-04-16 |
美商Ionis製藥公司 |
Yap1表現之調節劑
|
|
WO2020169696A1
(en)
|
2019-02-20 |
2020-08-27 |
Roche Innovation Center Copenhagen A/S |
Novel phosphoramidites
|
|
MX2021009950A
(es)
|
2019-02-20 |
2021-09-21 |
Roche Innovation Ct Copenhagen As |
Oligonucleotidos gapmeros de fosfonoacetato.
|
|
JP7503072B2
(ja)
|
2019-02-26 |
2024-06-19 |
ロシュ イノベーション センター コペンハーゲン エーエス |
オリゴヌクレオチドの製剤化方法
|
|
KR20210134003A
(ko)
|
2019-02-27 |
2021-11-08 |
스톡 테라퓨틱스, 인크. |
병태 및 질환의 치료를 위한 안티센스 올리고머
|
|
WO2020176771A1
(en)
|
2019-02-27 |
2020-09-03 |
Ionis Pharmaceuticals, Inc. |
Modulators of malat1 expression
|
|
EP3981431A4
(en)
|
2019-03-14 |
2023-06-28 |
Rena Therapeutics Inc. |
Nucleic acid complex for modulating ihh expression
|
|
TW202536179A
(zh)
|
2019-03-29 |
2025-09-16 |
美商Ionis製藥公司 |
用於調節ube3a-ats之化合物及方法
|
|
US11286485B2
(en)
|
2019-04-04 |
2022-03-29 |
Hoffmann-La Roche Inc. |
Oligonucleotides for modulating ATXN2 expression
|
|
CN113677374A
(zh)
|
2019-04-08 |
2021-11-19 |
国立大学法人东京医科齿科大学 |
肌疾病治疗用药物组合物
|
|
WO2020245233A1
(en)
|
2019-06-06 |
2020-12-10 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting atxn3
|
|
PL3956450T3
(pl)
|
2019-07-26 |
2025-12-22 |
Ionis Pharmaceuticals, Inc. |
Związki i sposoby modulowania gfap
|
|
WO2021054370A1
(ja)
|
2019-09-18 |
2021-03-25 |
国立大学法人東京医科歯科大学 |
核酸複合体
|
|
CN114502566B
(zh)
|
2019-10-11 |
2025-02-11 |
住友化学株式会社 |
核酸寡聚物的制造方法
|
|
EP4043565A4
(en)
|
2019-10-11 |
2024-01-24 |
National University Corporation Tokyo Medical and Dental University |
MODIFIED HETERONUCLEIC ACID
|
|
US20240148891A1
(en)
|
2019-10-18 |
2024-05-09 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
JP7644499B2
(ja)
*
|
2019-11-27 |
2025-03-12 |
国立大学法人東京科学大学 |
アンチセンス核酸の毒性を軽減する方法
|
|
EP4058032A4
(en)
|
2019-12-19 |
2024-01-10 |
Entrada Therapeutics, Inc. |
Compositions for delivery of antisense compounds
|
|
EP4081639A1
(en)
|
2019-12-24 |
2022-11-02 |
F. Hoffmann-La Roche AG |
Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv
|
|
EP4081217A1
(en)
|
2019-12-24 |
2022-11-02 |
F. Hoffmann-La Roche AG |
Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv
|
|
JP7858532B2
(ja)
|
2020-01-10 |
2026-05-14 |
ダイン セラピューティクス，インコーポレーテッド |
筋肉標的複合体および筋肉の健康に関連する遺伝子のモジュレーションのためのその使用
|
|
US20230090446A1
(en)
|
2020-01-28 |
2023-03-23 |
Universite De Strasbourg |
Antisense oligonucleotide targeting linc00518 for treating melanoma
|
|
CN115003680B
(zh)
|
2020-01-29 |
2025-01-28 |
住友化学株式会社 |
制备核酸寡聚物的方法
|
|
KR20220133878A
(ko)
|
2020-01-29 |
2022-10-05 |
스미또모 가가꾸 가부시끼가이샤 |
핵산 올리고머의 제조 방법
|
|
CN114929876A
(zh)
|
2020-01-31 |
2022-08-19 |
株式会社三和化学研究所 |
Atn1的反义寡核苷酸
|
|
AU2021225957A1
(en)
|
2020-02-28 |
2022-09-08 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating SMN2
|
|
WO2021177418A1
(ja)
|
2020-03-04 |
2021-09-10 |
日産化学株式会社 |
Ｃａｌｍ２のアンチセンスオリゴヌクレオチド
|
|
WO2021178374A2
(en)
*
|
2020-03-05 |
2021-09-10 |
Synerk Inc. |
Compounds and methods for reducing apoe expression
|
|
EP4123023A4
(en)
|
2020-03-16 |
2024-07-17 |
National University Corporation Tokyo Medical and Dental University |
Heteronucleic acid containing morpholino nucleic acid
|
|
CN115335387A
(zh)
|
2020-03-27 |
2022-11-11 |
住友化学株式会社 |
核酸寡聚物的制造方法
|
|
KR20230002814A
(ko)
*
|
2020-04-17 |
2023-01-05 |
더 유니버시티 오브 브리티쉬 콜롬비아 |
Tdp-43 및 fus 응집을 억제하기 위한 조성물 및 방법
|
|
TWI901676B
(zh)
|
2020-05-01 |
2025-10-21 |
美商Ionis製藥公司 |
調節ａｔｘｎ１之化合物及方法
|
|
US12338437B2
(en)
|
2020-05-11 |
2025-06-24 |
Stoke Therapeutics, Inc. |
OPA1 antisense oligomers for treatment of conditions and diseases
|
|
TW202216996A
(zh)
|
2020-06-29 |
2022-05-01 |
美商Ionis製藥公司 |
調節ｐｌｐ１之化合物及方法
|
|
KR20230034969A
(ko)
|
2020-07-09 |
2023-03-10 |
스미또모 가가꾸 가부시끼가이샤 |
핵산 올리고머의 제조 방법
|
|
US11638761B2
(en)
|
2021-07-09 |
2023-05-02 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
|
|
US11969475B2
(en)
|
2021-07-09 |
2024-04-30 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
US11633498B2
(en)
|
2021-07-09 |
2023-04-25 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
MX2023001222A
(es)
|
2020-07-28 |
2023-04-26 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para reducir la expresion de app.
|
|
IL300258A
(en)
|
2020-08-07 |
2023-03-01 |
Ionis Pharmaceuticals Inc |
Compounds and methods for modulating SCN2A
|
|
KR20230074205A
(ko)
|
2020-09-24 |
2023-05-26 |
스미또모 가가꾸 가부시끼가이샤 |
핵산 올리고머의 제조 방법
|
|
KR20230108728A
(ko)
|
2020-11-18 |
2023-07-18 |
아이오니스 파마수티컬즈, 인코포레이티드 |
앤지오텐시노겐 발현을 조절하기 위한 화합물 및 방법
|
|
WO2022117745A1
(en)
|
2020-12-03 |
2022-06-09 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting atxn3
|
|
TW202237843A
(zh)
|
2020-12-03 |
2022-10-01 |
瑞士商赫孚孟拉羅股份公司 |
靶向ａｔｘｎ３之反義寡核苷酸
|
|
KR20230117182A
(ko)
|
2020-12-04 |
2023-08-07 |
다인 세라퓨틱스, 인크. |
항체-올리고뉴클레오티드 복합체 및 그의 용도
|
|
AR124408A1
(es)
|
2020-12-18 |
2023-03-22 |
Ionis Pharmaceuticals Inc |
Compuestos y métodos para modular el factor xii
|
|
AU2021414227A1
(en)
|
2020-12-31 |
2023-07-06 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
WO2022162015A1
(en)
|
2021-01-26 |
2022-08-04 |
Universite Brest Bretagne Occidentale |
Novel stim1 splicing variants and uses thereof
|
|
US20220259601A1
(en)
*
|
2021-02-17 |
2022-08-18 |
Q-State Biosciences, Inc. |
Ube3a antisense therapeutics
|
|
US20220370487A1
(en)
*
|
2021-05-10 |
2022-11-24 |
Q-State Biosciences, Inc. |
Compositions targeting sodium channel 1.6
|
|
IL308353A
(en)
|
2021-05-10 |
2024-01-01 |
Entrada Therapeutics Inc |
Compositions and methods for modulating tissue distribution of intracellular therapies
|
|
CA3221584A1
(en)
|
2021-05-25 |
2022-12-01 |
National University Corporation Tokyo Medical And Dental University |
Heteronucleic acid containing scpbna or amna
|
|
EP4353266A4
(en)
|
2021-05-31 |
2026-04-29 |
Rena Therapeutics Inc |
LIGAND-BOND NUCLEIC ACID COMPLEX
|
|
US11753644B2
(en)
|
2021-06-18 |
2023-09-12 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing IFNAR1 expression
|
|
AU2022298774A1
(en)
|
2021-06-23 |
2023-12-14 |
Entrada Therapeutics, Inc. |
Antisense compounds and methods for targeting cug repeats
|
|
EP4389891A4
(en)
|
2021-08-19 |
2025-10-29 |
Univ Nat Corp Tokyo Medical & Dental |
MODIFIED HETERONUCLEIC ACID CONTAINING MORPHOLINO NUCLEIC ACID
|
|
WO2023026994A1
(ja)
|
2021-08-21 |
2023-03-02 |
武田薬品工業株式会社 |
ヒトトランスフェリンレセプター結合ペプチド－薬物コンジュゲート
|
|
US11833221B2
(en)
|
2021-09-01 |
2023-12-05 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds for reducing DMPK expression
|
|
US20250179486A1
(en)
|
2021-09-15 |
2025-06-05 |
National University Corporation Tokyo Medical And Dental University |
Heteronucleic acid including 2'-modified nucleoside
|
|
EP4410770A4
(en)
|
2021-09-28 |
2026-03-25 |
Sumitomo Chemical Co |
PROCESS FOR THE PRODUCTION OF PURIFIED DICHLOROACETIC ACID
|
|
US20260185102A1
(en)
|
2021-11-02 |
2026-07-02 |
Rena Therapeutics Inc. |
Ligand-binding nucleic acid complex
|
|
WO2023078883A1
(en)
|
2021-11-03 |
2023-05-11 |
F. Hoffmann-La Roche Ag |
Oligonucleotides for modulating apolipoprotein e4 expression
|
|
AU2022384619A1
(en)
|
2021-11-11 |
2024-04-11 |
F. Hoffmann-La Roche Ag |
Pharmaceutical combinations for treatment of hbv
|
|
JP2024547071A
(ja)
|
2021-12-20 |
2024-12-26 |
エフ． ホフマン－ラ ロシュ アーゲー |
トレオース核酸アンチセンスオリゴヌクレオチドおよびその方法
|
|
KR20240131441A
(ko)
|
2022-01-10 |
2024-08-30 |
오스퍼바이오 테라퓨틱스 인크. |
B형 간염 바이러스(hbv) 발현의 조절
|
|
WO2023141507A1
(en)
|
2022-01-20 |
2023-07-27 |
Genentech, Inc. |
Antisense oligonucleotides for modulating tmem106b expression
|
|
IL315546A
(en)
|
2022-03-16 |
2024-11-01 |
Empirico Inc |
GALNAC compositions to improve siRNA bioavailability
|
|
EP4488282A4
(en)
|
2022-03-23 |
2025-11-19 |
Sumitomo Chemical Co |
PROCESS FOR THE PRODUCTION OF NUCLEIC ACID OLIGOMERS
|
|
EP4499834A2
(en)
|
2022-03-28 |
2025-02-05 |
Empirico Inc. |
Modified oligonucleotides
|
|
IL316143A
(en)
|
2022-04-15 |
2024-12-01 |
Dyne Therapeutics Inc |
Muscle targeting complexes and formulations for the treatment of myotonic dystrophy
|
|
CN119403816A
(zh)
|
2022-07-22 |
2025-02-07 |
住友化学株式会社 |
寡核苷酸的制造方法
|
|
EP4563559A4
(en)
|
2022-07-28 |
2026-07-15 |
Sumitomo Chemical Co |
THIONIZATION SOLUTION
|
|
CN120659627A
(zh)
|
2022-07-29 |
2025-09-16 |
瑞泽恩制药公司 |
用于转铁蛋白受体（tfr）介导的脑和肌肉递送的组合物和方法
|
|
EP4332221A1
(en)
|
2022-08-29 |
2024-03-06 |
Roche Innovation Center Copenhagen A/S |
Threose nucleic acid antisense oligonucleotides and methods thereof
|
|
EP4581143A1
(en)
|
2022-08-29 |
2025-07-09 |
University of Rochester |
Antisense oligonucleotide-based anti-fibrotic therapeutics
|
|
JP2025532127A
(ja)
|
2022-09-23 |
2025-09-29 |
アイオーニス ファーマシューティカルズ， インコーポレーテッド |
Ｍｅｃｐ２発現を低減する化合物及び方法
|
|
WO2024073386A1
(en)
*
|
2022-09-29 |
2024-04-04 |
Celanese Eva Performance Polymers Llc |
Implantable medical device for the delivery of a nucleic acid
|
|
WO2024071099A1
(ja)
|
2022-09-29 |
2024-04-04 |
国立大学法人東京医科歯科大学 |
５'－シクロプロピレン修飾を含む核酸分子
|
|
JP7825064B2
(ja)
|
2022-10-27 |
2026-03-05 |
住友化学株式会社 |
オリゴヌクレオチドの製造方法
|
|
AU2023371614A1
(en)
|
2022-11-04 |
2025-05-15 |
Regeneron Pharmaceuticals, Inc. |
Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
|
|
AU2023379457A1
(en)
|
2022-11-14 |
2025-05-15 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
|
|
WO2024143276A1
(ja)
|
2022-12-26 |
2024-07-04 |
住友化学株式会社 |
オリゴヌクレオチドの製造方法
|
|
WO2024153586A1
(en)
|
2023-01-16 |
2024-07-25 |
Institut National De Recherche Pour L'agriculture, L'alimentation Et L'environnement |
Antisense molecules and their uses for the treatment of coronavirus infection, in particular the treatment of covid-19 related to sars-cov-2 infection
|
|
EP4680251A1
(en)
*
|
2023-03-14 |
2026-01-21 |
Thomas Jefferson University |
Compositions and methods for the treatment of cancer
|
|
KR20260021596A
(ko)
|
2023-04-05 |
2026-02-13 |
아이오니스 파마수티컬즈, 인코포레이티드 |
Pln 발현을 감소시키는 화합물 및 방법
|
|
WO2025047953A1
(ja)
|
2023-08-30 |
2025-03-06 |
株式会社Stratoimmune |
ＲａｓＧＲＰ４のアンチセンスオリゴヌクレオチド
|
|
WO2025059511A1
(en)
|
2023-09-15 |
2025-03-20 |
Praxis Precision Medicines, Inc. |
Elsunersen / prax-222 for use in the treatment of scn2a-related disorders
|
|
WO2025143262A1
(ja)
|
2023-12-28 |
2025-07-03 |
日産化学株式会社 |
カルバモイルエチル修飾を含有する二本鎖ｒｎａ
|
|
WO2025229953A1
(ja)
|
2024-04-30 |
2025-11-06 |
住友化学株式会社 |
オリゴヌクレオチドの製造方法
|
|
WO2026080442A2
(en)
|
2024-10-07 |
2026-04-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Compositions and methods for treating fibrotic and inflammatory diseases
|
|
WO2026105127A1
(en)
*
|
2024-11-17 |
2026-05-21 |
Sheba Impact Ltd. |
Antisense oligonucleotide (aso)-based methods for substrate reduction therapy for lysosomal storage diseases
|